StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Shares of NBRV stock opened at $0.00 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The firm’s 50 day simple moving average is $0.03. The firm has a market capitalization of $6,403.00, a PE ratio of 0.00 and a beta of 1.53.
Nabriva Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Nabriva Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Insider Buying Signals Upside for These 3 Stocks
- How to buy stock: A step-by-step guide for beginners
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.